相关实验视频
Updated: Jun 20, 2026

09:49
Routine Screening Method for Microparticles in Platelet Transfusions
Published on: January 31, 2018
补充剂过度激活是败血症相关凝血病的因果驱动因素:来自英国生物库的孟德尔随机化研究
Rong Liufu1, Mao-Mao Cao1, Yan Chen1
1State Key Laboratory of Complex Severe and Rare Diseases, Medical ICU, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.
概括
补充系统过度激活因果性地驱动了败血症中的凝血病. 这种单向的关系,特别是涉及C3,是基因支持和部分独立于炎症.
科学领域:
- 免疫学 免疫学 免疫学
- 遗传学 遗传学是一种遗传学.
- 败血症病理生理学病理生理学
背景情况:
- 败血症涉及补体系统和凝血之间的复杂相互作用.
- 补充剂过度激活和败血症引起的凝血病之间的因果关系尚不清楚.
研究的目的:
- 调查补充系统过度激活和败血症中的凝血病之间的因果关系.
- 使用孟德尔随机化来确定这种关系的方向性.
主要方法:
- 两个样本的孟德尔随机化 (MR) 使用英国生物银行GWAS数据.
- 补充水平和凝血病的全基因组关联研究 (GWAS).
- 逆方差加权 (IVW) 和多变量MR (MVMR) 分析,包括CRP的调整.
主要成果:
- 确定了高补充性败血症和凝血病 (例如,C3,F5) 的共享遗传位置.
- 证明C3水平对凝血病风险具有显著的积极因果作用 (P=0.0008).
- 建立了一个单向的因果途径,从补充激活到凝血病,独立于CRP.
结论:
- 补充系统过度激活是败血症中凝血病的因果驱动因素.
- 这些发现突出了C3作为败血症诱导的凝血病的关键调解者.
- 建议在毒症管理的补充途径内设置治疗点.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

